Literature DB >> 17009065

Clinical appearance of erythema migrans caused by Borrelia afzelii and Borrelia garinii--effect of the patient's sex.

Louise Bennet1, Carl-Johan Fraenkel, Ulf Garpmo, Anders Halling, Mikael Ingman, Katharina Ornstein, Louise Stjernberg, Johan Berglund.   

Abstract

AIM: The aim in this survey was to study the clinical characteristics of infections caused by Borrelia genospecies in patients with erythema migrans where borrelial origin was confirmed by polymerase chain reaction. The aim was also to study factors influencing the clinical appearance of erythema migrans.
METHODS: The study was conducted in southern Sweden from May 2001 to December 2003 on patients 18 years and older attending with erythema migrans at outpatient clinics. All erythema migrans were verified by polymerase chain reaction, photographed and categorized as "annular" or "non-annular" lesions. A logistic regression model was used to analyze relations between the appearance of the erythema migrans (i.e. annular or non-annular) and factors that influenced its clinical appearance.
RESULTS: A total of 118 patients, 54 women (45.8%) and 64 men (54.2%), fulfilled the inclusion criteria. Of these patients, 74% were infected by B. afzelii and 26% by B. garinii (p < 0.001). A total of 45% (38/85) of the erythema migrans were annular, 46% (39/85) were nonannular and 9.4% (8/85) were atypical. For men infected by B. afzelii, the odds ratio of developing non-annular erythema migrans was 0.09 (95% CI: 0.03-0.33) in comparison with women with the same infection.
CONCLUSIONS: In this prospective study of a large series of erythema migrans, where infecting genospecies were confirmed by polymerase chain reaction, the sex of patients infected with B. afzelii had a strong influence on the appearance of the rash. Patients infected by B. garinii more often had non-annular erythema migrans and a more virulent infection with more individuals presenting with fever, raised levels of C-reactive protein and seroreactivity in the convalescence sera.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009065     DOI: 10.1007/s00508-006-0659-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  27 in total

1.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

Review 2.  Gonadal steroids and immunity.

Authors:  N J Olsen; W J Kovacs
Journal:  Endocr Rev       Date:  1996-08       Impact factor: 19.871

3.  Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections.

Authors:  Sten-Anders Carlsson; Hans Granlund; Christian Jansson; Dag Nyman; Peter Wahlberg
Journal:  Scand J Infect Dis       Date:  2003

4.  Erythema chronicum migrans of Lyme disease.

Authors:  B W Berger
Journal:  Arch Dermatol       Date:  1984-08

5.  Determination of novel Borrelia genospecies in Swedish Ixodes ricinus ticks.

Authors:  Carl-Johan Fraenkel; Ulf Garpmo; Johan Berglund
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

6.  Transhemispheric exchange of Lyme disease spirochetes by seabirds.

Authors:  B Olsen; D C Duffy; T G Jaenson; A Gylfe; J Bonnedahl; S Bergström
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

Review 7.  Cutaneous manifestations of Lyme borreliosis. Clinical definitions and differential diagnoses.

Authors:  E Asbrink
Journal:  Scand J Infect Dis Suppl       Date:  1991

8.  Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis.

Authors:  A P van Dam; H Kuiper; K Vos; A Widjojokusumo; B M de Jongh; L Spanjaard; A C Ramselaar; M D Kramer; J Dankert
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

9.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Prevalence of Borrelia burgdorferi sensu lato-infected ticks on migrating birds.

Authors:  B Olsén; T G Jaenson; S Bergström
Journal:  Appl Environ Microbiol       Date:  1995-08       Impact factor: 4.792

View more
  5 in total

1.  Diagnostic Performance of the Novel BioPlex Lyme Serological Assays in European Patients with Lyme Disease.

Authors:  M E (Ewoud) Baarsma; Jeanine Ursinus; Hans L Zaaijer; Herman Kuiper; Joppe W Hovius
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

2.  Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States.

Authors:  Tjasa Cerar; Franc Strle; Dasa Stupica; Eva Ruzic-Sabljic; Gail McHugh; Allen C Steere; Klemen Strle
Journal:  Emerg Infect Dis       Date:  2016-05       Impact factor: 6.883

3.  Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice.

Authors:  Knut Eirik Eliassen; Reidar Hjetland; Harald Reiso; Morten Lindbæk; Hedda Tschudi-Madsen
Journal:  Scand J Prim Health Care       Date:  2017-02-28       Impact factor: 2.581

4.  Ixodes ricinus ticks removed from humans in Northern Europe: seasonal pattern of infestation, attachment sites and duration of feeding.

Authors:  Peter Wilhelmsson; Pontus Lindblom; Linda Fryland; Dag Nyman; Thomas G T Jaenson; Pia Forsberg; Per-Eric Lindgren
Journal:  Parasit Vectors       Date:  2013-12-20       Impact factor: 3.876

5.  Complement activation in individuals with previous subclinical Lyme borreliosis and patients with previous Lyme neuroborreliosis.

Authors:  Hanna Carlsson; Kerstin Sandholm; Haben Woldu Haddish; Lars Brudin; Kristina Nilsson Ekdahl; Ivar Tjernberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-31       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.